A Prospective Clinical Study to Evaluate the Safety and Effectiveness of Pulmonary Vein Isolation Plus Box Isolation of Fibrotic Areas With the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

Key Who May Qualify: - A diagnosis of recurrent symptomatic paroxysmal or persistent AF - Failure or intolerance of at least one antiarrhythmic drug (AAD) Class I or III Key Who Should NOT Join This Trial: - Long-standing persistent AF (sustained \>12 months) - Atrial fibrillation secondary to a reversible cause or of non-cardiac origin - History of thromboembolic events within the past six months - Myocardial infarction (MI)/percutaneous coronary intervention (PCI) within the last three months - Any cardiac surgery within the previous six months - Prior left atrial ablation or surgical procedure - Presence of an implanted cardiac device - Body mass index (BMI) \>40 kg/m\^2 - Left ventricular ejection fraction (LVEF) \<35% - Anterior-posterior left atrial (LA) diameter \>55mm Always talk to your doctor about whether this trial is right for you.